The molecular mediators that induce MI, the loss of myocardial regeneration, and the development of heart disease are all being researched more thoroughly. It's intriguing to think about how genetic factors could be used to modulate these disease mediators. DNA, RNA, or proteins may both be included in this operation. However, direct delivery of these biomolecules is not always effective. Using gene therapy methods, nanomedicine has elegantly attempted to reverse many gene polymorphisms and defects in complex diseases.The stability of these biomolecules, as well as their controlled release and passage through barriers to the operating site, can be aided by delivery systems. Precision-tailored vector delivery has been shown to reduce toxicity and improve drug availability. Currently, a variety of distribution systems are being evaluated, with the frontrunners incorporating security and conclusions being selected.New biological mediators, as well as the complex interactions within them, as well as their pharmacokinetic and pharmacodynamic profiles, will be discovered in the future. This opens the door to a more advanced delivery system that meets the biological requirements for maximum therapeutic efficacy.